Broad Biotech Patent Claims-the Saga Continues

There now is increased interest about the written description and enablement requirements for patent applications claiming antibodies. This may stem from the recent U.S. Supreme Court decision in Amgen v. Sanofi, finding lack of enablement for broad antibody claims….
By: Lathrop GPM
Previous Story

Federal District Court Denied Spoliation Motion Where Plaintiffs Attempted to Argue that a Bus Company Failed to Preserve Video

Next Story

Client Alert: IARC to Evaluate Automotive Gasoline and Oxygenated Additives in Early 2025